Final count shows overwhelming rejection of Mylan's pay practices

The final vote tally just released from Mylan’s annual shareholders meeting last week shows weak support for many of the generic drug giant’s long-time board members, while the company’s executive pay practices were rejected by an overwhelming 84 percent of votes cast.  READ MORE